Related Experiment Video
Updated: Jul 11, 2025

CD Spectroscopy to Study DNA-Protein Interactions
Published on: February 10, 2022
Global identification of SWI/SNF targets reveals compensation by EP400
Benjamin J E Martin1, Eileen F Ablondi2, Christine Goglia2
1Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Boston, MA 02115, USA.
Abstract:
Mammalian SWI/SNF chromatin remodeling complexes move and evict nucleosomes at gene promoters and enhancers to modulate DNA access. Although SWI/SNF subunits are commonly mutated in disease, therapeutic options are limited by our inability to predict SWI/SNF gene targets and conflicting studies on functional significance. Here, we leverage a fast-acting inhibitor of SWI/SNF remodeling to elucidate direct targets and effects of SWI/SNF. Blocking SWI/SNF activity causes a rapid and global loss of chromatin accessibility and transcription. Whereas repression persists at most enhancers, we uncover a compensatory role for the EP400/TIP60 remodeler, which reestablishes accessibility at most promoters during prolonged loss of SWI/SNF. Indeed, we observe synthetic lethality between EP400 and SWI/SNF in cancer cell lines and human cancer patient data. Our data define a set of molecular genomic features that accurately predict gene sensitivity to SWI/SNF inhibition in diverse cancer cell lines, thereby improving the therapeutic potential of SWI/SNF inhibitors.
Insights
A new SWI/SNF inhibitor reveals chromatin remodeling targets and identifies EP400/TIP60 as a compensatory mechanism. This finding predicts cancer cell sensitivity to SWI/SNF inhibition, improving therapeutic strategies.
Area of Science:
- Molecular Biology
- Genomics
- Cancer Research
Background:
- Mammalian SWI/SNF complexes regulate DNA accessibility by moving nucleosomes.
- Mutations in SWI/SNF are common in diseases, but therapeutic targets remain unclear.
Purpose of the Study:
- To identify direct SWI/SNF targets and functional consequences using a novel inhibitor.
- To explore compensatory mechanisms and predict therapeutic sensitivity.
Main Methods:
- Utilized a fast-acting SWI/SNF inhibitor to block chromatin remodeling.
- Assessed global chromatin accessibility and transcription changes.
- Analyzed compensatory roles of EP400/TIP60 and synthetic lethality in cancer cells.
Main Results:
- SWI/SNF inhibition led to rapid, global loss of chromatin accessibility and transcription.
- EP400/TIP60 compensated for SWI/SNF loss at promoters, but not enhancers.
- Synthetic lethality between EP400 and SWI/SNF was observed in cancer cell lines and patient data.
Conclusions:
- Identified molecular genomic features predicting SWI/SNF inhibitor sensitivity in cancer.
- Demonstrated a compensatory role for EP400/TIP60, revealing synthetic lethality.
- Enhanced the therapeutic potential of SWI/SNF inhibitors by predicting drug sensitivity.
Related Concept Videos
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...

